Education
About Us
Working with TipRanks
Follow Us
Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
AYTU Stock Chart & Stats
$2.13
-$0.06(-3.58%)
At close: 4:00 PM EST
$2.13
-$0.06(-3.58%)
Day’s Range― - ―
52-Week Range$0.95 - $2.82
Previous CloseN/A
Volume5.78K
Average Volume (3M)314.73K
Market Cap
$21.11M
Enterprise Value$6.79M
Total Cash (Recent Filing)$32.63M
Total Debt (Recent Filing)$1.86M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Feb 18, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding9,911,913
10 Day Avg. Volume289,104
30 Day Avg. Volume314,725
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.72
Price to Sales (P/S)0.21
P/FCF Ratio-6.32
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue0.11
Enterprise Value/Gross Profit0.16
Enterprise Value/Ebitda-1.24
Forecast
1Y Price Target
$9.17Price Target Upside330.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients.
Market StrategyAytu announced it signed an exclusive commercialization agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA for the treatment of major depressive disorder (MDD), which is already FDA-approved.
Product LaunchAytu is on pace to launch EXXUA for treating major depressive disorder in December 2025, which is expected to be Aytu’s primary focus and future growth driver.
Bears Say
ADHD Segment ChallengesThe ADHD segment, Aytu's primary source of revenue, experienced a decline and missed sales estimates due to various factors impacting the business.
Revenue PerformanceAytu reported F4Q25 results with total revenue of $15.1M, which was below both consensus and estimates, leading to a decrease in stock value.
Aytu BioScience News
AYTU FAQ
What was Aytu BioScience Inc’s price range in the past 12 months?
Aytu BioScience Inc lowest stock price was $0.95 and its highest was $2.82 in the past 12 months.
What is Aytu BioScience Inc’s market cap?
Aytu BioScience Inc’s market cap is $21.11M.
When is Aytu BioScience Inc’s upcoming earnings report date?
Aytu BioScience Inc’s upcoming earnings report date is Feb 18, 2026 which is in 76 days.
How were Aytu BioScience Inc’s earnings last quarter?
Aytu BioScience Inc released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.11.
Is Aytu BioScience Inc overvalued?
According to Wall Street analysts Aytu BioScience Inc’s price is currently Undervalued.
Does Aytu BioScience Inc pay dividends?
Aytu BioScience Inc does not currently pay dividends.
What is Aytu BioScience Inc’s EPS estimate?
Aytu BioScience Inc’s EPS estimate is -0.4.
How many shares outstanding does Aytu BioScience Inc have?
Aytu BioScience Inc has 9,911,913 shares outstanding.
What happened to Aytu BioScience Inc’s price movement after its last earnings report?
Aytu BioScience Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went up 1.456%.
Which hedge fund is a major shareholder of Aytu BioScience Inc?
Currently, no hedge funds are holding shares in AYTU
Company Description
Aytu BioScience Inc
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
AYTU Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company focused on significant upcoming product launches and managing existing portfolio challenges. While the performance of the ADHD portfolio and progress towards the EXXUA launch highlight growth and strategic focus, declines in certain segments and regulatory concerns pose challenges.View all AYTU earnings summariesAYTU Stock 12 Month Forecast
Average Price Target
$9.17
▲(330.52% Upside)
Technical Analysis
Ownership Overview
4.20% Insiders
0.69% Mutual Funds
28.96% Other Institutional Investors
63.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---